作者
Julio Chirinos, Patricio Lopez-Jaramillo, Evangelos Giamarellos-Bourboulis, Gonzalo Dávila-del-Carpio, Abdul Bizri, Jaime Andrade-Villanueva, Oday Salman, Carlos Cure-Cure, Nelson Rosado-Santander, Mario Cornejo Giraldo, Luz González-Hernández, Rima Moghnieh, Rapti Angeliki, María Cruz Saldarriaga, Marcos Pariona, Carola Medina, Ioannis Dimitroulis, Charalambos Vlachopoulos, Corina Gutierrez, Juan Rodriguez-Mori, Edgar Gomez-Laiton, Rosa Pereyra, Jorge Ravelo Hernández, Hugo Arbañil, José Accini-Mendoza, Maritza Pérez-Mayorga, Haralampos Milionis, Garyfallia Poulakou, Gregorio Sánchez, Renzo Valdivia-Vega, Mirko Villavicencio-Carranza, Ricardo Ayala-Garcia, Carlos Castro-Callirgos, Rosa Alfaro Carrasco, Willy Lecca Danos, Tiffany Sharkoski, Katherine Greene, Bianca Pourmussa, Candy Greczylo, Jesse Chittams, Paraskevi Katsaounou, Zoi Alexiou, Styliani Sympardi, Nancy Sweitzer, Mary Putt, Jordana Cohen
发表日期
2022
简介
Background Abnormal cellular lipid metabolism appears to underlie SARS-CoV-2 cytotoxicity and may involve inhibition of peroxisome proliferator activated receptor alpha (PPARα). Fenofibrate, a PPAR-α activator, modulates cellular lipid metabolism. Fenofibric acid has also been shown to affect the dimerization of angiotensin-converting enzyme 2, the cellular receptor for SARS-CoV-2. Fenofibrate and fenofibric acid have been shown to inhibit SARS-CoV-2 replication in cell culture systems in vitro. Methods We randomly assigned 701 participants with COVID-19 within 14 days of symptom onset to 145 mg of fenofibrate (nanocrystal formulation with dose adjustment for renal function or dose-equivalent preparations of micronized fenofibrate or fenofibric acid) vs. placebo for 10 days, in a double-blinded fashion. The primary endpoint was a ranked severity score in which participants were ranked across hierarchical tiers incorporating time to death, duration of mechanical ventilation, oxygenation parameters, subsequent hospitalizations and symptom severity and duration. ClinicalTrials. gov registration NCT04517396.
学术搜索中的文章
J Chirinos, P Lopez-Jaramillo… - 2022